Delcath director granted 22,500 stock options

DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock.

Rhea-AI Filing Summary

DELCATH SYSTEMS, INC. director Elizabeth Czerepak received a grant of stock options covering 22,500 shares of common stock. The options have an exercise price of $11.61 per share and are compensation rather than an open-market purchase.

The award vests at a rate of one-twelfth per month, with the first vesting on May 13, 2026 and monthly thereafter while she remains a director under the company’s 2020 Omnibus Equity Incentive Plan. Any unexercised options will expire the earlier of 10 years from the grant date or two years after her service ends.

Insider Trade Summary

Grant/Award: 22,500 shares

Grant/Award 1 txn

Insider CZEREPAK ELIZABETH

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,500 contracts (Direct)

Footnotes (1)

1. F1. The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service.

Key Figures

Option grant size: 22,500 options Exercise price: $11.61/share Underlying shares: 22,500 shares +3 more

6 metrics

Option grant size 22,500 options Stock Option (right to buy) granted to director

Exercise price $11.61/share Conversion or exercise price for granted options

Underlying shares 22,500 shares Common Stock underlying the stock options

Post-transaction options held 22,500 options Total options following transaction

Vesting schedule 1/12 per month Begins May 13, 2026 while serving as director

Maximum option term 10 years Expires earlier of 10 years from grant or 2 years after service

Key Terms

Stock Option (right to buy), 2020 Omnibus Equity Incentive Plan, vest and become exercisable, grant, award, or other acquisition

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2020 Omnibus Equity Incentive Plan financial

"subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended"

vest and become exercisable financial

"The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Delcath Systems (DCTH) director Elizabeth Czerepak report on this Form 4?

Elizabeth Czerepak reported receiving a grant of stock options for 22,500 shares of Delcath Systems common stock. These options are a compensation award, not an open-market share purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many Delcath Systems (DCTH) stock options were granted and at what price?

The filing shows a grant of 22,500 Delcath Systems stock options with an exercise price of $11.61 per share. This means she can buy up to 22,500 shares at $11.61, subject to vesting and the option’s expiration terms defined in the award.

What is the vesting schedule of Elizabeth Czerepak’s Delcath (DCTH) stock options?

The options vest and become exercisable in 12 equal monthly installments. Vesting begins on May 13, 2026, with one-twelfth vesting each month thereafter, as long as she continues serving as a director and meets the plan’s terms and conditions.

When do the reported Delcath Systems (DCTH) stock options expire?

The options expire on the earlier of 10 years from the grant date or two years from the last day of her service for vested options. After expiration, any unexercised options are no longer valid and cannot be used to purchase company shares.

Does this Delcath Systems (DCTH) Form 4 show a stock purchase or sale?

No, the Form 4 reflects a grant of stock options as compensation, coded as a grant or award acquisition. It does not show any open-market buying or selling of Delcath Systems shares by the director, only the receipt of option-based rights.

How many Delcath Systems (DCTH) options does the director hold after this transaction?

Following the reported grant, the director holds 22,500 stock options according to the filing. This figure reflects the total options from this award, which will vest over time and may be exercised later, subject to the plan’s conditions and expiration rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CZEREPAK ELIZABETH

(Last) (First) (Middle)

C/O DELCATH SYSTEMS, INC.,

566 QUEENSBURY AVENUE

(Street)

QUEENSBURY NEW YORK 12804

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DELCATH SYSTEMS, INC. [ DCTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$11.61	05/13/2026		A		22,500		(1)	(1)	Common Stock	22,500	$0	22,500	D

Explanation of Responses:

1. The option will vest and become exercisable at the rate of one-twelfth (1/12th) per month with the first such vesting to occur on May 13, 2026 and monthly thereafter for so long as the reporting person remains a director of the Issuer (and subject to the terms and conditions of the Issuer's 2020 Omnibus Equity Incentive Plan, as amended). The option will expire the earlier of 10 years from the grant date or, for vested options, two years from the last day of service.

	/s/ Gerard Michel, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)